Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-09-15
Mercier Johanna Files Gilead Sciences (GILD) Form 4 - September 15, 2026
Mercier Johanna sold 3.0K GILD shares worth $432.6K in this Form 4 filing, reported to the SEC on 2026-09-15.
- Insider
- Mercier Johanna
- Issuer
- Gilead Sciences, Inc. GILD · NASDAQ
- Filed
- Period
- 2026-09-15
- Accession
- 0001782135-26-000033
- Source
- Official filing on sec.gov ↗
Transactions (3)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Mercier Johanna | 2026-09-15 | Sell | 1.6K | $143.69 | $229.9K | Direct |
| Mercier Johanna | 2026-09-15 | Sell | 800 | $144.46 | $115.6K | Direct |
| Mercier Johanna | 2026-09-15 | Sell | 600 | $145.29 | $87.2K | Direct |
| Net change | −3.0K | −$432.6K | ||||
About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious diseases with unmet medical needs. Gilead Sciences specializes in therapeutic areas including HIV, viral hepatitis, oncology, inflammation, respiratory conditions, and cardiovascular disease. Its current portfolio includes prescription medicines and specialty treatments used in hospitals, clinics, and long-term care settings, supporting patients across global markets. The company also maintains an active pipeline in virology, oncology, and inflammation, reinforcing its role as a major provider of branded therapies in modern healthcare. Headquartered in Foster City, California, Gilead Sciences serves physicians, healthcare systems, and patients through a diversified product portfolio centered on infectious disease and specialty care.
Track GILD insider activity
Get alerted when Gilead Sciences, Inc. executives buy or sell their shares.